Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
NEW YORK, Aug. 25, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
The Phase II clinical trial will investigate the effect of ZLX-1 on insomnia, and is a critical milestone for this novel insomnia treatment on its way to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the Phase IIb trial to follow.
“We are thrilled to finally see the the clinical trial taking off,” says Blake Insomnia Therapeutics president and CEO Birger Jan Olsen. “It is an important milestone for the company and also for me personally, as I’ve been looking forward to this moment for quite some time now.”
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 [email protected]
